Edwards Lifesciences Corp reports $1.74 billion revenue for quarter ended June 30, 2026, up 13.6%

ยท EW

Edwards Lifesciences Corp reported revenue of $1.74 billion for the quarter ended June 30, 2026, an increase of 13.6% from the same quarter a year earlier ($1.53 billion).

For the same period it posted net income of $241.9 million, down 27.4%, or $0.42 per diluted share (0.56 a year earlier).

That is a net margin of 13.9%.

On Sanad's AAOIFI Standard 21 screen, Edwards Lifesciences Corp is currently compliant: interest-bearing debt is 1% of market capitalisation (limit 30%), and impure income is 2.8% of revenue (limit 5%).

Source: 10-Q filed with the U.S. Securities and Exchange Commission on August 4, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Edwards Lifesciences Corp news